FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112732435> ?p ?o ?g. }

• W2112732435 abstract "The involvement of protein kinase CK2 in sustaining cancer cell survival could have implications also in the resistance to conventional and unconventional therapies. Moreover, CK2 role in blood tumors is rapidly emerging and this kinase has been recognized as a potential therapeutic target. Phase I clinical trials with the oral small ATP-competitive CK2 inhibitor CX-4945 are currently ongoing in solid tumors and multiple myeloma.We have analyzed the expression of CK2 in acute myeloid leukemia and its function in cell growth and in the response to the chemotherapeutic agent daunorubicin We employed acute myeloid leukemia cell lines and primary blasts from patients grouped according to the European LeukemiaNet risk classification. Cell survival, apoptosis and sensitivity to daunorubicin were assessed by different means. p53-dependent CK2-inhibition-induced apoptosis was investigated in p53 wild-type and mutant cells.CK2a was found highly expressed in the majority of samples across the different acute myeloid leukemia prognostic subgroups as compared to normal CD34+ hematopoietic and bone marrow cells. Inhibition of CK2 with CX-4945, K27 or siRNAs caused a p53-dependent acute myeloid leukemia cell apoptosis. CK2 inhibition was associated with a synergistic increase of the cytotoxic effects of daunorubicin. Baseline and daunorubicin-induced STAT3 activation was hampered upon CK2 blockade.These results suggest that CK2 is over expressed across the different acute myeloid leukemia subsets and acts as an important regulator of acute myeloid leukemia cell survival. CK2 negative regulation of the protein levels of tumor suppressor p53 and activation of the STAT3 anti-apoptotic pathway might antagonize apoptosis and could be involved in acute myeloid leukemia cell resistance to daunorubicin." @default.
• W2112732435 created "2016-06-24" @default.
• W2112732435 creator A5013236194 @default.
• W2112732435 creator A5019076398 @default.
• W2112732435 creator A5020164618 @default.
• W2112732435 creator A5021321101 @default.
• W2112732435 creator A5029007744 @default.
• W2112732435 creator A5041064105 @default.
• W2112732435 creator A5042867938 @default.
• W2112732435 creator A5049960947 @default.
• W2112732435 creator A5058373325 @default.
• W2112732435 creator A5066814162 @default.
• W2112732435 creator A5068000268 @default.
• W2112732435 creator A5071722839 @default.
• W2112732435 creator A5077204314 @default.
• W2112732435 creator A5086902762 @default.
• W2112732435 creator A5090660779 @default.
• W2112732435 date "2013-10-12" @default.
• W2112732435 modified "2023-10-13" @default.
• W2112732435 title "Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity" @default.
• W2112732435 cites W1526999767 @default.
• W2112732435 cites W1558580388 @default.
• W2112732435 cites W194331471 @default.
• W2112732435 cites W1963678818 @default.
• W2112732435 cites W1967725310 @default.
• W2112732435 cites W1972603998 @default.
• W2112732435 cites W1980905165 @default.
• W2112732435 cites W1981387221 @default.
• W2112732435 cites W1981619037 @default.
• W2112732435 cites W1988356885 @default.
• W2112732435 cites W1988769784 @default.
• W2112732435 cites W1992677777 @default.
• W2112732435 cites W1996547558 @default.
• W2112732435 cites W2001472847 @default.
• W2112732435 cites W2005894923 @default.
• W2112732435 cites W2006411424 @default.
• W2112732435 cites W2011332360 @default.
• W2112732435 cites W2026084872 @default.
• W2112732435 cites W2030510544 @default.
• W2112732435 cites W2033181253 @default.
• W2112732435 cites W2033354569 @default.
• W2112732435 cites W2070217465 @default.
• W2112732435 cites W2071907638 @default.
• W2112732435 cites W2074281710 @default.
• W2112732435 cites W2076015888 @default.
• W2112732435 cites W2077236132 @default.
• W2112732435 cites W2077385921 @default.
• W2112732435 cites W2081681244 @default.
• W2112732435 cites W2084507055 @default.
• W2112732435 cites W2091660633 @default.
• W2112732435 cites W2096743657 @default.
• W2112732435 cites W2102605856 @default.
• W2112732435 cites W2103562758 @default.
• W2112732435 cites W2108805958 @default.
• W2112732435 cites W2110602561 @default.
• W2112732435 cites W2112635043 @default.
• W2112732435 cites W2116858301 @default.
• W2112732435 cites W2123283162 @default.
• W2112732435 cites W2132732528 @default.
• W2112732435 cites W2137724647 @default.
• W2112732435 cites W2147358450 @default.
• W2112732435 cites W2150099809 @default.
• W2112732435 cites W2150121030 @default.
• W2112732435 cites W2151575257 @default.
• W2112732435 cites W2170976471 @default.
• W2112732435 cites W2319955241 @default.
• W2112732435 cites W2558450893 @default.
• W2112732435 doi "https://doi.org/10.1186/1756-8722-6-78" @default.
• W2112732435 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3852751" @default.
• W2112732435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24283803" @default.
• W2112732435 hasPublicationYear "2013" @default.
• W2112732435 type Work @default.
• W2112732435 sameAs 2112732435 @default.
• W2112732435 citedByCount "45" @default.
• W2112732435 countsByYear W21127324352014 @default.
• W2112732435 countsByYear W21127324352015 @default.
• W2112732435 countsByYear W21127324352016 @default.
• W2112732435 countsByYear W21127324352017 @default.
• W2112732435 countsByYear W21127324352018 @default.
• W2112732435 countsByYear W21127324352019 @default.
• W2112732435 countsByYear W21127324352020 @default.
• W2112732435 countsByYear W21127324352021 @default.
• W2112732435 countsByYear W21127324352022 @default.
• W2112732435 countsByYear W21127324352023 @default.
• W2112732435 crossrefType "journal-article" @default.
• W2112732435 hasAuthorship W2112732435A5013236194 @default.
• W2112732435 hasAuthorship W2112732435A5019076398 @default.
• W2112732435 hasAuthorship W2112732435A5020164618 @default.
• W2112732435 hasAuthorship W2112732435A5021321101 @default.
• W2112732435 hasAuthorship W2112732435A5029007744 @default.
• W2112732435 hasAuthorship W2112732435A5041064105 @default.
• W2112732435 hasAuthorship W2112732435A5042867938 @default.
• W2112732435 hasAuthorship W2112732435A5049960947 @default.
• W2112732435 hasAuthorship W2112732435A5058373325 @default.
• W2112732435 hasAuthorship W2112732435A5066814162 @default.
• W2112732435 hasAuthorship W2112732435A5068000268 @default.
• W2112732435 hasAuthorship W2112732435A5071722839 @default.
• W2112732435 hasAuthorship W2112732435A5077204314 @default.
• W2112732435 hasAuthorship W2112732435A5086902762 @default.
• W2112732435 hasAuthorship W2112732435A5090660779 @default.

• next